Posaconazole
Title: Posaconazole
CAS Registry Number: 171228-49-2
CAS Name: 2,5-Anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1S,2S)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1H-1,2,4-triazol-1-yl)-D-threo-pentitol
Additional Names: (3R-cis)-4-[4-[4-[4-[5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)tetrahydrofuran-3-ylmethoxy]phenyl]piperazin-1-yl]phenyl]-2-[1(S)-ethyl-2(S)-hydroxypropyl]-3,4-dihydro-2H-1,2,4-triazol-3-one
Manufacturers' Codes: Sch-56592
Trademarks: Noxafil (Schering-Plough)
Molecular Formula: C37H42F2N8O4
Molecular Weight: 700.78
Percent Composition: C 63.41%, H 6.04%, F 5.42%, N 15.99%, O 9.13%
Literature References: Orally active triazole antifungal. Prepn: A. K. Saksena et al., WO 9517407; eidem, US 5661151 (1995, 1997 both to Schering); eidem, Tetrahedron Lett. 37, 5657 (1996). Comparative antifungal spectrum: A. Cacciapuoti et al., Antimicrob. Agents Chemother. 44, 2017 (2000). Pharmacokinetics, safety and tolerability: R. Courtney et al., ibid. 47, 2788 (2003). HPLC determn in serum: H. Kim et al., J. Chromatogr. B 738, 93 (2000). Review of development: A. K. Saksena et al. in Anti-Infectives: Recent Advances in Chemistry and Structure Activity Relationships (Royal Soc. Chem., Cambridge, 1997) pp 180-199; and clinical efficacy in fungal infections: R. Herbrecht, Int. J. Clin. Pract. 58, 612-624 (2004).
Properties: White solid, mp 170-172°.
Melting point: mp 170-172°
Therap-Cat: Antifungal.
Keywords: Antifungal (Synthetic); Triazoles.

Others monographs:
Endobenzyline BromideButylated HydroxytoluenePine TarNalorphine
MephenytoinBarium Manganate(VI)p-IodophenolPepsin
Magnesium Monoperoxyphthalate2,3:6,7-DibenzphenanthreneTamarindN,N'-Dimethylthiourea
Meldrum's AcidButralinC-Curarine IMelanins
©2016 DrugLead US FDA&EMEA